BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15695942)

  • 1. Insulin sensitizers: past, present and future.
    Siddiqui NI
    Mymensingh Med J; 2005 Jan; 14(1):1-2. PubMed ID: 15695942
    [No Abstract]   [Full Text] [Related]  

  • 2. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
    Inzucchi SE
    Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
    [No Abstract]   [Full Text] [Related]  

  • 3. Insulin: thoroughly modern therapy.
    Isley WL
    Endocr Pract; 2004; 10(3):289-90. PubMed ID: 15310550
    [No Abstract]   [Full Text] [Related]  

  • 4. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E; Schnell O
    Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract]   [Full Text] [Related]  

  • 5. Insulin sensitization therapy and the heart: focus on metformin and thiazolidinediones.
    Wong AK; Struthers AD; Choy AM; Lang CC
    Heart Fail Clin; 2012 Oct; 8(4):539-50. PubMed ID: 22999238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new shine on an old med. The story of metformin's past, present, and possible future.
    Gebel E
    Diabetes Forecast; 2010 Dec; 63(12):48-51. PubMed ID: 21192531
    [No Abstract]   [Full Text] [Related]  

  • 7. Why I initiate therapy with two insulin sensitizers in patients with type 2 diabetes.
    Bell DS
    Endocr Pract; 2003; 9(1):98-101. PubMed ID: 12917098
    [No Abstract]   [Full Text] [Related]  

  • 8. Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin.
    Derosa G; Salvadeo SA; D'Angelo A; Fogari E; Ragonesi PD; Ciccarelli L; Piccinni MN; Ferrari I; Gravina A; Maffioli P; Cicero AF
    Arch Med Res; 2008 May; 39(4):412-9. PubMed ID: 18375253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications.
    Molavi B; Rassouli N; Bagwe S; Rasouli N
    Vasc Health Risk Manag; 2007; 3(6):967-73. PubMed ID: 18200815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Insulin sensitizers is now approved as monotherapy as well. Lowering blood pressure with added effects].
    MMW Fortschr Med; 2003 Oct; 145(41):47. PubMed ID: 14655486
    [No Abstract]   [Full Text] [Related]  

  • 11. beta-cell function and anti-diabetic pharmacotherapy.
    Del Prato S; Bianchi C; Marchetti P
    Diabetes Metab Res Rev; 2007 Oct; 23(7):518-27. PubMed ID: 17883249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Against insulin resistance. Insulin sensitizers].
    Verspohl EJ; Weiland F
    Pharm Unserer Zeit; 2002; 31(3):280-92. PubMed ID: 12071125
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug treatment of type 2 diabetes in adults.
    Lowey A
    Nurs Stand; 2005 Nov 23-29; 20(11):55-64; quiz 66. PubMed ID: 16320965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues.
    Ratziu V; Caldwell S; Neuschwander-Tetri BA
    Hepatology; 2010 Dec; 52(6):2206-15. PubMed ID: 21105109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [2-year data of large clinical comparative studies. Type 2 diabetes: lasting metabolic control with pioglitazone].
    MMW Fortschr Med; 2004 Jul; 146(29-30):48-9. PubMed ID: 15540563
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin and pioglitazone: Effectively treating insulin resistance.
    Staels B
    Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
    Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addressing insulin resistance in Type 1 diabetes.
    Pang TT; Narendran P
    Diabet Med; 2008 Sep; 25(9):1015-24. PubMed ID: 19183305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.